Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (411-420 of 463) with videos related to

Pageof 47
Sort By:
Cellular and Molecular Gastroenterology and Hepatology|April 4, 2021
Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination TherapyRoman Kosoy, Seunghee Kim-Schulze, Adeeb Rahman, et al.
Gut|May 1, 2019
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free miceJoana Torres, Jianzhong Hu, Akihiro Seki, et al.
Archives of Iranian Medicine|February 4, 2024
Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle EastHasan Vosoghinia, Bahar Saberzadeh-Ardestani, Amir Anushiravani, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Gastroenterology|December 11, 2020
Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their BabiesEun Soo Kim, Leonid Tarassishin, Caroline Eisele, et al.
Alimentary Pharmacology & Therapeutics|March 12, 2022
A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel diseaseKatherine Falloon, Benjamin Cohen, Ashwin N Ananthakrishnan, et al.
United European Gastroenterology Journal|August 19, 2025
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational SurveyAna Catarina Bravo, Sara Godt Christensen, Mette Julsgaard, et al.
Inflammatory Bowel Diseases|November 28, 2013
Challenges in designing a national surveillance program for inflammatory bowel disease in the United StatesMillie D Long, Susan Hutfless, Michael D Kappelman, et al.
Pageof 47

Showing results (411-420 of 463) with videos related to

Sort By:
Pageof 47
Cellular and Molecular Gastroenterology and Hepatology|April 4, 2021
Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination TherapyRoman Kosoy, Seunghee Kim-Schulze, Adeeb Rahman, et al.
Gut|May 1, 2019
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free miceJoana Torres, Jianzhong Hu, Akihiro Seki, et al.
Archives of Iranian Medicine|February 4, 2024
Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle EastHasan Vosoghinia, Bahar Saberzadeh-Ardestani, Amir Anushiravani, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Gastroenterology|December 11, 2020
Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their BabiesEun Soo Kim, Leonid Tarassishin, Caroline Eisele, et al.
Alimentary Pharmacology & Therapeutics|March 12, 2022
A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel diseaseKatherine Falloon, Benjamin Cohen, Ashwin N Ananthakrishnan, et al.
United European Gastroenterology Journal|August 19, 2025
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational SurveyAna Catarina Bravo, Sara Godt Christensen, Mette Julsgaard, et al.
Inflammatory Bowel Diseases|November 28, 2013
Challenges in designing a national surveillance program for inflammatory bowel disease in the United StatesMillie D Long, Susan Hutfless, Michael D Kappelman, et al.
Pageof 47